- 05:59 PM Tata Equity P/E Fund declares Dividend
- 05:52 PM Bharti Airtel has support at Rs 190-200: Sukhani
- 05:48 PM What does PM's Afghan comment mean for India-Pak p...
- 05:37 PM Buy hotel stocks on correction: Sukhani
- 05:35 PM Buy NIIT Tech on dips; avoid Patni: Sudarshan Sukh...
- 05:35 PM UTI Services Industries Fund declares dividend
- 05:34 PM IMF official warns of bubbles in emerging markets
- 05:32 PM Want washboard abs, toned legs? Climb stairs say e...
- 05:31 PM Don`t kiss Santa, he may have the flu says Hungary...
- 05:30 PM Buy sugar stocks on dip: Sudarshan Sukhani



Broking house, Sharekhan is bullish on Wockhardt and has recommended buy rating on the stock with a target of Rs 552.
Sharekhan report on Wockhardt:
Wockhardt has received the approval of the US Food and Drug Authority (US FDA) for marketing painkiller tablets, containing a combination of Dextropropoxyphene napsylate and Acetaminophen (DPN+APAP), in the US market. The DPN+APAP combination is the generic version of Xanodyne Pharma's patented product, Darvocet- N. It is one of the more potent analgesic drugs and is widely used all over the world for control of various kinds of pain.
Implication of drug approval
The US market for the DPN+APAP combination is over $100 million. The product has been off patent for years and so any significant price erosion is less likely. However the market for the product is highly competitive, as there are about 14 players including the innovator of the product. Wockhardt is the world's largest manufacturer of Dextropropoxyphene and the company's products based on this drug are sold all over the world. With this approval, it can launch the product in the USA soon.
Assuming a 5% market share for Wockhardt and marginal price erosion, we estimate this product to contribute Rs20.25 crore to Wockhardt's top line in FY2008E. Wockhardt, with end-to-end integrated capabilities and own marketing front-end for the product, can generate a margin of 30%, leading to incremental earnings per share (EPS) of just Rs0.50 per share.
Valuation and view
Wockhardt's US initiatives are progressively gaining momentum with the launch of every new product. It has now 16 ANDA approvals out of total fillings of 45. It is planning to file additional 30+ ANDAs in the US markets during CY2007 and expects at least seven new product approvals from the US FDA in H1CY2007. With this the company is targeting a growth of 50% plus in the US business in CY2007.
Wockhardt plans to achieve domestic growth of at least 20% through its new product launches, entry into newer therapeutic areas like dermatology and oncology, and a 30% growth in the Dumex business. On the other hand, the Pinewood acquisition in Ireland would boost the European business. Also, Wockhardt is expected to be one of the few Indian companies to benefit from the opening up of the biogeneric space in the regulated markets like the USA and Europe. With legislations in the USA underway, we believe Wockhardt will be able to launch its biogeneric products in these markets in 2009-10. With limited competition in this segment, Wockhardt is expected to reap handsome gains.
At the current market price of Rs362, the stock is available at 12.0x its estimated CY2007 and 10.4x its estimated CY2008 earnings, on a fully diluted basis. The valuations seem very attractive at these levels and should be viewed as a strong opportunity to get into the stock. We maintain our Buy recommendation on the stock with a price target of Rs 552.
|
Stock Advice
|
|
|
Business
Business News | Economy | Earnings | BSE NSE Notices
General News
Current Affairs | Politics | World News | Sports | Entertainment
Corporate Strategy
Management | Advertising | Marketing | Legal
Personal Finance
Tax | Insurance | Credit Cards | Loans | Property | Retirement | Investment Help | Financial Planning | Fixed Income
Markets
Local Market | Global Market | Market Cues | Analysis | Expert & FII outlook | Brokerage Recomendation
Stocks
Stocks in News | Expert Advice | ADRs & GDRs | IPO
Mutual Funds
News | Advice | MF Analysis | Fund Managers Views
Lifestyle
Travel | Wellness | Technology | Auto| Books
-
Most Read
-
Most Viewed
- 10 Companies that FIIs love
- Corrections in '10 to be more aggressive, violent: JPMorgan

- 10 companies that MF managers love
- Bollywood actress Shilpa Shetty marries Raj Kundra
- LyondellBasell development positive for RIL: PN Vijay

- Ignore Buffett, gold`s time has come
- Shilpa Shetty marries Raj Kundra
- Ganeshaspeaks: Market prediction for Nov 23
- Tata Equity P/E Fund declares Dividend
Source: Moneycontrol.com
- Bharti Airtel has support at Rs 190-200: Sukhani
Source: CNBC-TV18
- Buy hotel stocks on correction: Sukhani
Source: Moneycontrol.com
- Buy NIIT Tech on dips; avoid Patni: Sudarshan Sukhani
Source: Moneycontrol.com
- China`s Haitong Securities buys Hong Kong rival
Source: ft.com
- KSIDC in pact with FACT for trade centre
Source: Business Line
- GIC Re may have to pay Rs100cr for IOC's Jaipur fire claims
Source: Business Line
- Co-operative dairies seek restraint on oil-meal exports
Source: Business Line






















